CAH patients with the Bcl1 variant of the GC receptor gene—which increases the receptor’s activity—could have higher BMI, waist circumference, and systolic blood pressure [37], while GRα works oppositely and decreases GR activity, and could be related to a lower risk of development cardiometabolic complications, regardless of higher GC dose [38]. The gene discussed is CCND1; the disease is congenital adrenal hyperplasia.